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Abstract  
Addiction has for several decades come to be viewed as a disorder of the dopamine 
neurotransmitter system; however, this view has not led to new treatments. We review the 
origins of the dopamine theory of addiction and discuss the ability of addictive drugs to elicit 
the release dopamine in the human striatum. There is robust evidence that stimulants 
increase striatal dopamine release, some evidence for alcohol, but little if any for cannabis 
and opiates. Moreover, there is good evidence that striatal dopamine receptor availability 
and dopamine release are diminished in individuals with stimulant or alcohol dependence 
but not in individuals with opiate, nicotine or cannabis dependence. These observations 
have implications for understanding reward and treatment responses in various addictions. 
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Addiction is one of the great health problems facing the world today. Deaths from addictive 
substances, including tobacco and alcohol, amount to many millions of people per year1, and 
currently available treatments for addiction have limited efficacy and application. Thus, there 
is a great need to better understand the brain mechanisms that are involved in addiction so 
that new, better-targeted interventions can be developed.  
Brain research made a major breakthrough in the 1970s when the potential role of 
dopamine in addiction was discovered. This breakthrough stemmed from the finding of Olds 
and Milner2 that rats would willingly and repeatedly self-stimulate particular areas in the brain 
with electricity, a process they called positive reinforcement. These areas were subsequently 
shown to comprise, in part, a set of dopamine neurons3, which explained why drugs that 
enhanced the actions of this neurotransmitter  (for example, stimulants) increased electrical 
self-stimulation4. A subsequent series of largely US studies revealed that blocking dopamine 
receptors with neuroleptic drugs impaired the reinforcing effects of stimulants in rats and 
primates. This research clearly placed dopamine as the central neurotransmitter in stimulant 
addiction5 and suggested it had roles in reward, motivation and incentive behaviour6. 
The next conceptual breakthrough came when a group of researchers in Sardinia, 
who pioneered the technique of brain microdialysis in rats, discovered that a range of other 
drugs of abuse (that is, not just stimulants) increased dopamine release in the nucleus 
accumbens, which is located in the ventral striatum7. This led to a general theory of 
addiction, which was that addictive drugs released dopamine but psychoactive drugs, that 
were not addictive, did not. The field developed rapidly from this point, with multiple 
replications of the early animal findings of dopamine being released by “addictive” drugs  
and reported confirmations in humans using neurochemical imaging. These findings led to 
immense investment in research to alter dopamine neurotransmitter function as a route to 
treat addiction. Disappointingly, despite four decades of intense research effort, this theory 
has not led to new treatments. In this Opinion article, we chart the history of the dopamine 
theory of addiction, explore the current evidence for this theory and suggest that initial 
optimism must now be cautioned with a more objective view of the role of dopamine in 
addiction.  
 
Dopamine and the drug ‘high’  
Studying in vivo dopamine function in humans became possible in the mid 1990’s with the 
development of radiotracer imaging techniques, such as 11C-raclopride positron emission 
tomography (PET) and 123I-IBZM single-photon emission tomography (SPECT). These 
tracers can be used to measure the availability of striatal dopamine D2/3 receptors and 
changes in striatal dopamine levels in the synapse (BOX 1)8.  
The critical breakthrough in imaging the human dopamine system in addiction came 
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in 1994 when it was demonstrated that the combination of intravenous infusion of a central 
stimulant drug and SPECT or PET neurochemical imaging of dopamine D2/3 receptors 
could be used to indirectly measure dopamine release in the human striatum (BOX 1)9, 10. 
The magnitude of this increase was later shown to predict the euphoria10 or ‘high’11 produced 
by the drug. This was interpreted as proving that the experience of pleasure (the rewarding 
action) of stimulant drugs in humans was mediated by striatal dopamine release, just as in 
rats 7. This was a powerful message that many researchers sought to develop. A succession 
of other human studies followed, which showed that alcohol12, 13, tobacco 14, ketamine 15 and 
cannabis 16 increase striatal dopamine release in healthy participants and in non-dependent 
drug users, thereby providing support for the dopamine theory of addiction (FIG. 1).  
Quite rapidly, the dopamine theory of addiction became generally accepted by the 
field, so that drugs which induced dopamine release were considered to pose a risk of 
abuse. An example of such a drug is modafinil, which is used to treat narcolepsy. A 11C-
raclopride dopamine imaging study found that modafinil produced an increase in dopamine 
release 17. This finding was interpreted to mean that modafinil carries a potential risk for 
abuse, despite the increase in dopamine release not being associated with an increase in 
‘liking’ scores17, and prior clinical evidence showing that modafinil was not reinforcing18. The 
dopamine theory of reward had a profound effect on the development of drugs that target the 
brain. Pharmaceutical companies routinely used rodent microdialysis assays of ventral 
striatal dopamine release to estimate the presumed abuse potential of new drugs, discarding 
compounds such as potential novel antidepressants if they elevated dopamine (D. J. N., 
unpublished observation). This is particularly concerning given the latest work using 
optogenetics to control dopamine neurons in mice shows that dopamine activity in ventral 
striatum is vital in resilience against depression19. 
However, studies of alcohol20, cannabis21, 22 and ketamine 23, 24 showed that these 
abused drugs do not inevitably induce dopamine release in humans. Moreover, unlike with 
stimulants, an association between striatal dopamine release and pleasurable or hedonic 
effects of these substances was less apparent. For instance, there was no relationship 
between increased striatal dopamine release and any behavioural, subjective or 
physiological effects of cannabis16, 21. In the case of alcohol, impulsivity and intoxication, but 
not ‘high’, were associated with increased dopamine levels12, 20.  
Despite these inconsistencies and the fact that all these drugs produced less 
dopamine release than intravenous administration of methylphenidate, a prevailing view 
developed that that the dopamine system had a central role in addiction that was applicable 
to all addictive drugs. Dopamine became characterized as the ‘pleasure’ neurotransmitter in 
human brain; that is, the one that produces reward.25-27 .This model of addiction even made 
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the cover of Time magazine http://content.time.com/time/covers/0,16641,19970505,00.html] 
and is widely quoted as a fact in current text books and by Wikipedia (for example, see the 
Wikipedia entries for “Reward system” and “Dopamine”). 
From the beginning there were doubts about whether this theory applied to drugs 
other than stimulants and even whether dopamine release was central to the rewarding 
effects of stimulants in humans28. Studies in rats showed that dopamine receptor blockade 
did not dampen the rewarding actions of opiates (for example, see29), and subsequent 
clinical trials revealed that blocking dopamine receptors was generally ineffective in blocking 
the rewarding effects of stimulants in humans 28 or in treating human addiction (even 
stimulant addiction)30. Moreover, several studies found that opiate administration was not 
associated with striatal dopamine release in opiate dependence. For example, a study in 
individuals addicted to heroin revealed that an intravenous dose of 50mg heroin had no 
effect on striatal dopamine levels despite producing a very pronounced euphoric ‘high’31. 
This finding was subsequently replicated in a study that further showed that expectation of a 
heroin reward (in the absence of actual heroin administration) also was not associated with 
dopamine release32.  
Various studies of nicotine mostly suggest that this drug causes a small increase in 
ventral striatal dopamine levels. For example, smoking cigarettes has been shown to 
produce a 7% reduction in 11C-raclopride PET binding (when compared with smoking de-
nicotinised cigarettes)33, whereas amphetamine produces a 10–20% reduction in the binding 
of this ligand 34-42 (FIG. 1). However, another study (in a small cohort) found that intranasal 
nicotine administration had no effect on ventral striatal dopamine release43. This finding may 
be consistent with the idea that some of the effects of tobacco are due, in part, to the burning 
of tobacco-producing substances that block monoamine oxidase B — the enzyme that 
degrades dopamine44. 
Studies of Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of 
cannabis, found that this compound had even smaller effects on striatal dopamine release 
than nicotine. Administration of oral THC was associated with a non-significant reduction of 
around 2.5% in ventral striatal 11C-raclopride binding21, inhaled THC was linked with a 
significant reduction of around 3.5% in ventral striatal 11C-raclopride binding16, and 
intravenous THC was associated no significant change in 123I-IBZM SPET binding22. The 
changes in 11C-raclopride reported here for THC were all less than the test–retest variability 
of the tracer45, which means that it is possible that they are the result of normal variation in 
the PET signal rather than being produced by THC administration. Although THC 
administration produced marked behavioural effects in all of these studies, such as 
perceptual distortions, cognitive disorganisation21 and even psychotic symptoms22, it seems 
that these cannot be satisfactorily explained by striatal dopamine release.  
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Lower  dopamine function?  
If the dopamine system is critically and universally involved in dependence to all drugs, we 
might expect changes in dopamine function to be apparent across all addictions. Two 
markers of abnormal dopamine function in drug dependence have emerged: the lower 
availability of striatal dopamine receptors and the diminished release of striatal dopamine in 
response to a pharmacological challenge (so-called blunting).  
 
Lower striatal dopamine receptor availability. Early radio-tracer imaging studies revealed 
that cocaine users had lower striatal dopamine D2/3 receptor availability than matched 
controls46. This was attributed to the effects of cocaine: cocaine induces dopamine release, 
which could be expected to downregulate post-synaptic dopamine receptors, leading to 
reduced receptor availability. This result has since been replicated in further cohorts of 
cocaine 36, 47-51 and methamphetamine users 52-54. Moreover, at least in cocaine addiction, 
this reduction in receptor radiotracer binding has been shown to result from the decreased 
expression of postsynaptic dopamine D2/3 receptors, rather than to higher synaptic 
dopamine concentrations that would compete with the radio-tracer 49 or to altered receptor 
affinity for dopamine 50. Decreased dopamine receptor availability has also been reported in 
individuals who are alcohol-dependent55-60 and, interestingly, higher striatal dopamine 
receptor availability may be protective against alcohol dependence in high-risk individuals 
(relatives of individuals with alcohol dependence)61. 
However, differences in striatal dopamine receptor availability have not been as 
convincingly demonstrated in other addictions. Three studies have reported that individuals 
with opiate addiction have lower striatal dopamine receptor availability than healthy 
participants62-64, whereas we have found no change in receptor availability with opiate 
addiction31. In nicotine addiction, two related studies have reported lower striatal dopamine 
receptor availability in male but not female cigarette smokers 65, 66 and three studies have 
found no differences in receptor availability between individuals who smoke and healthy non-
smokers irrespective of gender67-69. There is no evidence of changes in striatal dopamine 
receptor availability in cannabis addiction70-74, and we could not find any published studies 
on such changes in ecstasy or ketamine users.  
The observation of lower striatal dopamine D2/3 receptor availability in drug 
dependence also presents something of a paradox. One might predict that if striatal 
dopamine release was pleasurable, then lower receptor availability would to lead to a 
reduction in this effect. However, a seminal study by Volkow and colleagues found the 
opposite; namely, individuals with low striatal dopamine D2/3 receptor levels (as measured 
by 11C-raclopride PET) reported more pleasurable effects from stimulants75, 76. Animal 
studies have also supported this finding. For example, in rats, low dopamine D2/3 receptor 
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levels in the striatum predict more cocaine 77 but not heroin self-administration 78, and in 
monkeys, higher striatal D2/3 receptor levels are associated with less cocaine intake79. In 
addition, increasing dopamine receptors (through viral vector-mediated expression of the 
receptors) in the ventral striatum of dependent rats reduces both cocaine 80 and alcohol 
intake 81.  
These findings present a real challenge to the original theory that dopamine release 
is responsible the euphoric effect of abused substances. If dopamine acting through D2/3 
receptors is necessary to experience a drug ‘high’, then lower receptor availability should 
result in less, rather than more, rewarding drug effects.  
 
Blunted dopamine release in dependence. In many, but not all addictions, individuals 
show a blunting of striatal dopamine release (that is, the release of striatal dopamine is 
decreased in these individuals compared with healthy individuals) after a pharmacological 
challenge with either the misused drug or a stimulant. This phenomenon was first reported in 
1997, in cocaine-dependent participants after a methylphenidate challenge 82 and has been 
replicated several times in stimulant-dependent participants36, 51. Decreased dopamine 
release has also been demonstrated in opiate dependence after a methylphenidate 
challenge 64 and in alcohol dependence after an amphetamine challenge 57, 60 (FIG. 2). By 
contrast, no marked blunting of dopamine release was found in cannabis dependence after 
an amphetamine challenge 72.  
Recent studies show that the extent of blunted striatal dopamine release in stimulant 
addiction may predict treatment response and vulnerability to addiction. In cocaine users, 
low stimulant-induced dopamine release was associated with a preference for cocaine to 
money 36 and worse treatment outcomes 51. An elegant study of young people at ultra-high 
familial risk of addiction who used stimulants occasionally but were not yet dependent 
showed that amphetamine-induced dopamine release in these individuals was reduced 
compared with that in well-matched controls 83. One interpretation of these data is that low 
dopamine release is a vulnerability to addiction, thus turning the dopamine theory on its 
head; instead of being the cause of addiction, dopamine might, if anything, have a role in 
resilience against becoming dependent and may be crucial for recovery from addiction 51.  
However, it is also possible that ultra-high risk participants had not become addicted 
because they experienced less dopamine release.  
 
 
 
 
 
7 
 
Addiction to the dopamine theory?  
It is worth reflecting on why enthusiasm for the universal dopamine theory of addiction 
developed and then came to dominate the addiction field. There are several interacting 
factors. First, the animal dialysis studies were so novel and compelling and were seemingly 
confirmed by the beautiful studies of Schultz, which showed that dopamine neurons fired in 
response to rewards in monkeys 84. However, the relative discrepancies in the magnitude of 
dopamine release elicited by different drugs 7 should have given the field pause for thought. 
The stimulants produced striatal dopamine elevations that were many-fold greater than 
those produced by the other drugs, yet human experience suggests that stimulants are not 
more pleasurable or addictive 85. Findings from studies investigating only stimulants 
(generally cocaine or amphetamine) were often discussed as though they applied to all 
addictions, even though there was no evidence for such an assumption 86. Indeed, where 
studies have been conducted using the same animal models, it is clear that stimulants differ 
from opioids, for example in terms of the effects of low dopamine receptor number and drug 
self-administration   77,78.  
Second, the methylphenidate experiment in humans showed such a clear 
relationship between dopamine release and the perceived ‘high’ that it appeared mechanistic 
— the more dopamine release the bigger the ‘high’ 75. However, what was overlooked was 
the fact that methylphenidate and other stimulants act specifically on the dopamine system 
to increase dopamine levels. Thus, dopamine must be the proximal mediator of any 
psychological response to stimulants, and it should not be surprising that the change in 
striatal dopamine release correlates with the subjective ‘high’. However, this is an 
association rather than proof that the change in striatal dopamine levels mediates the ‘high’ 
for stimulants. For other psychoactive drugs that only indirectly act on  dopamine neurons — 
such as alcohol and nicotine that act via modulating dopaminergic neuronal firing in the 
ventral tegmental area  — the association between changes in dopamine levels and ‘high’ 
has been harder to show. 
Increased dopamine release has also been reported in rewarding activities such as 
playing computer games 87, the placebo response to L-dopa 88, in meditation 89 and eating 
behaviours 90. These findings have been used to ‘prove’ the dopamine theory of addiction, 
as they associate rewarding activities with dopamine release and so generalize the model to 
one that says all rewarding activities must be mediated by dopamine release. However, 
these studies imaged small numbers of participants and are often not replicated. The 
apparent rush to publish that any given pleasure-inducing drug or behaviour can induce 
dopamine release reflects one of the more worrying and pervasive aspects of science today 
— the pre-eminence given to reporting ‘positive’ data in support of currently influential 
theories. There is a concern that the classic Popperian approach to science, namely refuting 
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hypotheses, may be lost in the desire to publish papers that ‘prove’ the theory and which are 
then well cited but are often not replicated.  
 
Does dopamine have other roles?  
Dopamine has many roles in normal brain function. In the cortex, dopamine is important for 
executive functions such as attention and working memory91; in the basal ganglia it is 
necessary for motivational salience, reward and fluent motor function; and in the 
hypothalamus it regulates prolactin release. Dopamine also has been shown to have a major 
role in the pathogenesis of a proportion of cases of psychosis 92 and to be involved in 
positive mood in humans 93.  
Changes in dopamine function in the basal ganglia can lead to compulsive-type 
behaviours. One theory of dopamine’s involvement in stimulant addiction is that the initial 
pleasurable effects of these drugs are detected in the nucleus accumbens, and that with 
repetitive use of the drugs, the drug taking behaviour becomes encoded as habit in the 
caudate and putamen, through progressive activation of the spiral of interacting striatal-
cortical circuits 94, 95. 
As in rats, dopamine receptor availability in humans might relate to impulsivity (which 
itself is a risk factor for addiction) 96, 97. It has been proposed that low D2/3 receptor 
availability and low dopamine release in the striatum — as described in substance addiction, 
obesity and attention deficit hyperactivity disorder (ADHD) — are neurobiological markers of 
increased impulsivity 96. The relationship between impulsivity and dopaminergic function has 
been investigated in another disorder with high levels of impulsivity, pathological gamblers 
(that is, individuals addicted to gambling). This disorder, was recently re-categorized from an 
‘impulse control disorder’ in DMS-IV to a ‘behavioural addiction ’in DSM-5 due to clinical and 
cognitive similarities with substance addiction. Thus pathological or disordered gambling 
serves as a useful model to study addiction in the absence of any drug-induced changes in 
neurotransmitter function 98.  
In contrast to substance addiction, no differences in baseline D2/3 receptor 
availability have been found in pathological gamblers compared with healthy controls 99, 100. 
However, in one of these studies, striatal D2/3 receptor availability was inversely correlated 
with mood-related or ‘rash’ impulsiveness 100 and in the other, D2/3 receptor availability 
positively correlated with impulsiveness in the substantia nigra, a dopamine D3 receptor-rich 
brain region99. Unlike the blunted stimulant-related dopamine release that is seen in 
substance addiction, dopamine release was increased in the dorsal striatum after 
amphetamine administration in pathological gamblers compared with healthy volunteers101. 
This increase in dorsal striatal dopamine was predicted by the availability of D3 receptors, 
and the authors of this study proposed that D3-related mechanisms might contribute to 
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sensitization in this behavioural addiction101. The finding of increased stimulant-related 
dopamine release in pathological gamblers would also be consistent with the development of 
pathological gambling that is associated with dopamine replacement therapy in Parkinson’s 
disease. Indeed, patient’s with Parkinson’s disease with impulsive-compulsive behaviours, 
such as pathological gambling, show increased ventral striatal dopamine release after the 
presentation of rewarding cues102 in a similar way to cocaine users who show increased 
dorsal striatal dopamine release after the presentation of cocaine related cues103.    
Therefore, depending on the disorder associated with impulsivity, either lower or 
higher dopaminergic function has been found. It may be that rather than a linear relationship, 
an inverted-U type of response function for dopamine underpins the relationship with 
impulsivity such that an increase or decrease in dopamine may be required to improve 
inhibitory control; for example, an increase in dopamine may improve inhibitory control in 
ADHD but a decrease in dopamine may improve such control in gambling associated with 
dopamine replacement in Parkinson disease.  
Dopamine may also have a role in regulating the motivation to seek drugs. The 
induction of craving is associated with cue-induced striatal dopamine release in cocaine 
users 103-105, although this is not the case in heroin addicts 32. Dopamine has been proposed 
to have a role in motivation more generally 94, which could explain why in stimulant users, it 
might both drive use and be necessary for recovery from addiction. Dopamine also has a 
role in executive function 106 (which includes inhibitory control) and, by acting through a top-
down cortico–striatal mechanism, may have a role in preventing addiction and other 
dyscontrol disorders such as overeating 107.  
There is further evidence to support a possible protective role for dopamine in some 
drug users. A study in non-treatment seeking stimulant-dependent individuals 108 showed 
that the dopamine D2/3 receptor agonist pramipexole had different effects on psychological 
performance in a Stroop task and related functional MRI measures in individuals with high 
drug-related compulsivity versus individuals with low drug-related compulsivity. If this finding 
is replicated with cocaine and in people with other drug dependencies, it might lead to a 
more sophisticated view of dopamine in addiction and, potentially, to targeted interventions 
such as dopamine-promoting agents in people with addiction who exhibit impulsivity. 
Moreover, these results found using pramipexole108 may explain the partial efficacy of 
dopamine receptor agonists such as bromocriptine109, and dopamine metabolism inhibitors 
such as disulfiram30 in the treatment of alcohol and cocaine dependence, respectively. 
Other aspects of dopamine functioning in addiction such as the role of extra-striatal 
dopamine and the influence of drug cues on dopamine responses and future research needs 
are outlined in BOX 2.  
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Limitations 
Neurochemical imaging has provided crucial advances in our understanding of the role of 
the human dopamine system in addiction; however, there are limitations associated with the 
imaging technique and with the populations that have been imaged.  
Current dopamine radiotracers bind to D2/3 receptors irrespective of their synaptic 
location and most, with the exception of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-
naphtho[1,2-b][1,4]oxazin-9-ol (11C-PHNO) which preferentially binds to D3 receptors, bind 
to both dopamine D2 and D3 receptors. This means that for most studies it is difficult to 
assess whether differences in dopamine radiotracer binding between populations reflect 
altered D2 or D3 receptor availability. It also means that it is not possible to determine 
whether differences in binding reflect alterations in pre- or postsynaptic D2/3 receptors, 
although as animal studies show that the majority of striatal dopamine D2/3 receptors are 
localised postsynaptically110, most groups have interpreted differences as changes in 
postsynaptic D2/3 receptors. The sensitivity of neurochemical imaging to lower levels of 
dopamine release produced by pharmacological challenges is also limited by the variability 
in the PET or SPECT imaging signal, so that changes of 5% or less in binding could be a 
result of lower levels of dopamine release or variability in the signal. This is an important 
limitation as a primate study has shown that, at least for the SPECT radiotracer 123I-IBZM, 
which has a lower resolution than PET radiotracers such as11C]-raclopride, a 1% decrease in 
binding equates to a 40% increase in dopamine release111.  
There are also limitations in the types of populations imaged; the large majority of 
studies have imaged dependent populations and only a few (for example, see REF.83) have 
imaged those at high risk of developing addictions. This means that we do not know whether 
the changes in dopamine function reported in dependence are a consequence of substance 
use or are present before the onset of addiction and may mediate vulnerability.  
 The fact that there are only few dopamine neurochemical imaging studies available 
for the majority of the investigated substances, combined with the problem of different 
methods employed to define striatal regions (the latter partly due to the gradual improvement 
of scanning techniques over the past few decades), means that conducting meta-analyses in 
order to synthesize findings across each addiction has so far proven to be challenging.   
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Conclusions 
The dopamine theory of reward and addiction, which states that dopamine release mediates 
reward and so leads to addiction, has had huge traction. However, it became accepted as a 
‘universal’ theory without properly accounting for findings from studies in different drug 
addictions that did not support the theory. Tellingly, the dopamine theory has not led to any 
new treatments for addiction. We suggest that the role of dopamine in addiction is more 
complicated than the role proposed in the dopamine theory of reward. We propose that 
dopamine has a central role in addiction to stimulant drugs, which act directly via the 
dopamine system, but that it has a less important role, if any, in mediating addiction to other 
drugs, particularly opiates and cannabis.  
Addiction is a complex mixture of behaviours and attitudes that vary from drug to 
drug and from user to user, and it is unlikely that a single neurotransmitter could explain 
every aspect of addiction. We foresee that addiction will be conceptualised as a multiple 
neurotransmitter disorder in which the dopamine system is central to stimulant addiction but 
in which other neurotransmitter systems, such as the endogenous opiate or GABA systems, 
have important roles in other drug addictions. For example, endogenous opiates have been 
shown to be released by stimulants 112 and alcohol 113; higher opiate receptor availability has 
been found in cocaine 114, 115, opiate 116 and alcohol dependency 117-119; and alcohol 
dependence and pathological gambling can, to some extent, be treated with opioid 
antagonists such as nalmefene 120-122. Moreover, individuals with alcohol dependence have 
lower limbic GABAA receptor availability 
123, whereas participants with a history of cigarette 
smoking have higher limbic GABAA receptor availability 
124.  
In conclusion, this account of the rise and fall of the universal dopamine theory of 
addiction serves as a lesson in neuroscience research. Unifying theories, though intrinsically 
appealing, should be subject to careful scrutiny just like other theories — and perhaps even 
more so, as they can lead the field into directions that ultimately prove to be unfruitful.  
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Box 1 | Imaging dopamine receptors and dopamine release 
 
Imaging dopamine in the human striatum.  
Positron emission tomography (PET) and single-photon emission computed tomography 
(SPECT) are quantitative radioactive imaging techniques that can be used to measure the 
availability of receptors and transporters, as well as the release of neurotransmitters. In the 
case of the dopamine system, radiotracers such as 11C-raclopride (for PET) and [123I]-
iodobenzamide (for SPECT) can reliably measure the availability of dopamine D2/3 
receptors in the human striatum, the brain area with the highest density of these receptors. 
This includes the ventral striatum (also known as the nucleus accumbens), the region of the 
striatum that seems particularly involved in the acquisition of drug addiction. Most D2/3 
radiotracers, and in particular the ones with agonist properties such as 
 [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol (11C-PHNO), 
also have the ability to compete with the brain’s endogenous dopamine to bind to D2/3 
receptors125. Increases in extracellular dopamine levels elicited by pharmacological 
challenges, such as with methylphenidate 126 or amphetamine10, or non-pharmacological 
manipulations, such as stress, playing a video game or cue-induced drug craving8, can be 
detected as a decrease in the radiotracer binding due to increased competition for the 
striatal D2/3 receptor (for a review, see REF8).  
 
Extrastriatal dopamine imaging  
The development of higher affinity radiotracers for D2/3 receptors such as 18F-fallypride, 
((S)-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-bromo-2,3-dimethoxybenzamide) (18F-FLB 457) 127 
and [11C]-PHNO 128 has made it possible to image these receptors in brain regions outside 
the striatum (for example, in the frontal cortex), where the density of D2/3 receptors is lower. 
Radiotracers such as 11C-propyl-norapomorphine and in particular 11C-PHNO not only have 
high-affinity agonist properties but also have a higher affinity for dopamine D3 receptors over 
D2 receptors. This additional quality enables quantification of D3 availability and release in 
key areas of the brain in addiction such as the globus pallidum, ventral tegmental area, 
amygdala and hypothalamus129.  
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Box 2 | Key Issues and perspectives for future research 
  
To optimise our understanding about the relationship between the human dopamine system 
and addictive drugs, future research should consider a number of questions. First, who is 
being imaged? In selecting research participants, it is crucial to carefully describe factors 
that likely influence dopamine function, such as the lifetime use of alcohol and drugs, prior or 
current treatments, and periods of and current length of abstinence. Most individuals with a 
drug addiction use more than one substance and, other than tobacco smoking, such 
comorbidity is usually an exclusion criterion for studies in addiction. Selection of a control 
group that matches potentially important confounders — such as intelligence quotient or 
years of education, family history and alcohol, tobacco and other drug use — can be 
challenging. 
 Second, how is dopamine release induced? Stimulants are traditionally used in 
studies to increase dopamine levels. However, this pharmacological challenge may not be 
salient to individuals with addiction. For instance, many individuals with alcohol use 
disorders do not find stimulants rewarding, so in these individuals, any changes in dopamine 
levels that are induced by stimulants reflect what is available for release but does not inform 
us about ‘dopamine and reward’. Indeed, in such individuals, stimulant administration may 
be experienced as aversive. In some studies, addicted individuals were administered their 
‘drug-of-choice’, but not in the way they would normally self-administer it (for example, 
nicotine inhalators versus smoking), thereby reducing the salience of the drug, which could 
affect dopamine responses. An inherent limitation of PET protocols is that the drug-taking 
context cannot be simulated, but at least pharmacological and behavioural challenges 
should be optimised to reflect ‘usual’ drug behaviour.  
 Third, what is the role of cortical dopamine function? Most neurochemistry studies in 
addiction have imaged dopamine function in the human striatum. Such studies do not 
capture the importance of dopamine in mediating processes that are key to addiction, such 
as compulsion and executive function, which are largely cortical. We suggest that an 
important step for future studies is to focus on cortical dopamine function in addictions, 
particularly as great advances in human cortical dopamine imaging have been made over 
the past decade.  
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Figure 1 | The effect of abused substances on human ventral striatal dopamine 
release The studies contained in the figure use the the dopamine D2/3 receptor PET 
radiotracer 11C-raclopride to investigate the effect of abused substances on dopamine 
release in the ventral striatum. Decreases in 11C-raclopride PET binding occurs as a 
consequence of increased competition between dopamine and the tracer and so percentage 
decreases in 11C-raclopride binding reflect increased synaptic ventral striatal dopamine 
levels. These studies show consistent significant increases in ventral striatal dopamine 
levels produced by amphetamine and alcohol administration, less consistent increases 
produced by nicotine, and non-significant or small increases associated with diamorphine, 
THC or ketamine administration. The data presented here are derived from published 
studies describing changes in the ventral striatum, as this striatal area is the most relevant 
one to the theory of reward and dopamine; some studies are therefore not represented since 
data were available only for whole striatum. *Studies in which the change in 11C-raclopride 
binding was reported as non-significant. THC, Δ9-tetrahydrocannabinol. Data from REFs12-16, 
21, 23, 24, 31-43, 130-132. The studies contained in the figure are broadly comparable although there 
is some variability in the number participants imaged between studies and statistical tests 
used (largely t-tests). 
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Figure 2 |Investigating diminished ventral striatal dopamine release in addictions. 
These studies use the dopamine PET radiotracer 11C-raclopride to investigate whether 
diminished (‘blunted’) ventral striatal dopamine release occurs after administration of a 
stimulant (amphetamine or methylphenidate) in a range of substance addictions.  Decreases 
in 11C-raclopride PET binding occurs as a consequence of increased competition between 
dopamine and the tracer and so percentage decreases in 11C-raclopride binding reflect 
increased synaptic ventral striatal dopamine levels. The studies contained in the figure 
demonstrate significantly diminished ventral striatal dopamine release in alcohol, cocaine 
and heroin dependent individuals, and also in individuals at ultra-high risk to develop 
addiction, but no diminished release in cannabis or methamphetamine users. We selected 
studies which administered either amphetamine or methylphenidate as these directly target 
the dopamine system to ensure that any differences in dopamine levels would reflect 
changes in this system. For each study, the percentage change in 11C-raclopride binding is 
given for healthy participants and for the addicted population whose substance of addiction 
is depicted by the bar colour. The error bars show standard deviation. *Denotes a significant 
difference (according to the original study) in 11C-raclopride binding between the healthy 
participant and addiction groups. Data from REFs36, 51, 54, 57, 60, 64, 72, 83. Volkow and 
colleagues60 do not report standard deviation in change in 11C-raclopride PET binding. The 
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studies contained in the figure are broadly comparable although there is some variability in 
the number participants imaged between studies and statistical tests used (largely t-tests).  
 
 
